Clinical Trials
4 trialsNCT00275431 2011-06-29
Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies
Ascenta Therapeutics
Phase 2 Completed
NCT00440388 2010-08-27
Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma
Ascenta Therapeutics
Phase 2 Completed
NCT00544960 2010-08-27
A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer
Ascenta Therapeutics
Phase 2 Completed
NCT00286780 2010-08-13
Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia
Ascenta Therapeutics
Phase 2 Completed